ERBB2 and cholangiocarcinoma: Moreover, 36.4% of ORR and 7.4 months of DoR have been observed in 8 HER2-positive CCA patients (five patients for IHC3+, three patients for IHC2+/ISH+ patients, and one HER2-low) [180].